COVID-19: Dornase alfa
Dornase alfa is used to help treat cystic fibrosis. For funded access to the medicine, clinicians must submit Special Authority form which is reviewed by PHARMAC's Cystic Fibrosis panel.
Page last updated: 17 April 2020
We've changed some requirements to allow people to continue to access the medicine without needing to see a clinician face to face. This will take effect on 1 April 2020.
For patients aged 5 years and older
We've removed the requirement for spirometry before the initial Special Authority application.
For renewal applications, clinicians can assess patients over the phone to ascertain whether the treatment is beneficial.
For patients under 5 years old
PHARMAC has removed all criteria that require clinic attendance. This applies to both initial and renewal Special Authority applications.
The clinician can use a telephone consultation to decide whether the patient is benefiting from the treatment.
Cystic fibrosis panel renewal applications
For patients with a dornase alfa Special Authority approval that was due to expire in March, April and May 2020 – we extended the Special Authority by 3 months without requiring a renewal application.
This was a manual process. We emailed clinicians to confirm the extensions. Clinicians will need to let patients know if they have had an extension to their approval; we are unable to do this.
After this initial extension, we anticipate that the clinician will need to apply to renew the application as usual.
The Special Authority form will be available for download from the entry in the Schedule.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email firstname.lastname@example.org
Last updated: 17 April 2020